Allogene Therapeutics ALLO Business Segments — Operating Expenses

Similar metrics at other companies

VRDNReportable Segment — Operating Expenses

$116.19M+23.8%

PCVXReportable Segment — Operating Expenses

$345.85M+91.3%

REPLReportable Segment — Operating Expenses

$71.87M+8.9%

BCAXReportable Segment — Total Operating Expenses

$60.24M+44.2%

SLMReportable Segment — Operating Expenses

$170.36M+10.9%

MMIReportable Segment — Operating Expenses

$174.57M+16.8%

Questions, answered.

What is Allogene Therapeutics's business segments — operating expenses?

Allogene Therapeutics (ALLO) reported business segments — operating expenses of $46.09M in Q1 2026.

How has Allogene Therapeutics's business segments — operating expenses changed year-over-year?

Allogene Therapeutics's business segments — operating expenses decreased by 29.3% year-over-year, from $65.19M to $46.09M.

What is the long-term trend for Allogene Therapeutics's business segments — operating expenses?

Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — operating expenses has grown at a -20.1% compound annual growth rate (CAGR), from $327.83M to $209.32M.

What does business segments — operating expenses mean?

This metric represents the total cash and non-cash costs incurred to operate the business segment during the reporting period. It is a primary indicator of the company's burn rate and overall operational scale. Investors use this to evaluate the company's ability to manage its financial resources while advancing its clinical pipeline.